Australia's Leading Ophthalmic Magazine Since 1975

     Free Sign Up     

Australia's Leading Ophthalmic Magazine Since 1975

     Free Sign Up     
Tech

Implant allows 15 months between treatments for AMD

03/12/2018
Share:
Neovascular age-related macular degeneration (nAMD) patients have gone 15 months between treatments after being implanted with a device containing high concentrations of ranibizumab (Lucentis), according to new research.

The Phase II LADDER study of the implantable delivery system tracked 220 patients who were randomised to one of three concentration groups of ranibizumab (10 mg/mL, 40 mg/mL, or 100 mg/mL) in an implantable device, or given a conventional monthly injection of ranibizumab (.5 mg).

Patients treated with the highest ranibizumab concentration could go a median of 15 months before needing a refill and the port delivery treatment was deemed as effective as monthly injections.

“Fewer injections and office visits is exciting,” lead investigator Professor Carl Regillo said.

“But more importantly, we think it will translate into better visual outcomes because in the real world, patients get less treatment than they need. If you’re a week or two late for a visit from time to time, you may have a decline in vision, and you can’t always recover from that. It’s a relentlessly progressive disease.”

The data showed in patients receiving the 100 mg/mL ranibizumab, about 80% went more than six months without needing to refill their medication. In the 10 mg/mL and 40 mg/mL groups, 63.5% and 71.3% went six months or more, respectively.

In a separate study, faricimab – the first bispecific antibody designed for the eye – compared well with monthly ranibizumab for AMD patients.

According to the Phase II STAIRWAY study, at 52 weeks faricimab patients dosed either every 16 weeks or every 12 weeks demonstrated vision outcomes comparable to ranibizumab dosed every four weeks.

Results of the study were presented at the American Academy of Ophthalmology’s annual meeting.

largeleaderboard
advertisement





rectangle
advertisement
Editor's Suggestion
Hot Stories



OR
 

Subscribe for Insight in your Inbox

Get Insight with the latest in industry news, trends, new products, services and equipment!